Health Condition 1: Q213- Tetralogy of Fallot
Conditions
Interventions
Intervention1: Topical Tranexamic Acid: Route Topical (Diluted Tranexamic Acid is instilled into mediastinal cavity). Dose 50mg/kg. Frequency & Duration once before closure.
Control Intervention1: Int
Sponsors
Nil
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age more than one year 2. SpO2 less than 80 3. Consecutive patients meeting the above criteria over the 18-month study period.
Exclusion criteria
Exclusion criteria: 1.Emergency surgery 2. Weight less than 6kg 3. Pre-existing renal impairment or Neurologic event (e.g., seizure, stroke, or other neurological deficit) 4. Plt less than 75000 5. INR more than 1.5 6. Allergy to tranexamic acid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative blood loss (cumulative chest-drain output)Timepoint: First 24 hours) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To compare total blood products transfused within 24 hours after surgery. 2.To assess incidence of re-exploration for bleeding. 3.To evaluate postoperative haemoglobin and haematocrit at Immediate, 6 and 24 hours. 4.To document occurrence of thromboembolic complications and seizures. 5.To compare duration of mechanical ventilation & ICU stay.Timepoint: Till patient is in ICU | — |
Countries
India
Contacts
Public ContactNeeti Makhija
AIIMS, NEW DELHI
Outcome results
None listed